Titscher R
Wien Klin Wochenschr. 1978 Dec 22;90(24):874-5.
A pilot study is reported on the results achieved with the cytostatic agent dacarbacinum (DTIC) on previously untreated, inoperable bronchogenic carcinomas which had been histologically and/or cytologically verified. Altogether there were 16 patients, i.e. 13 males and 3 females. DTIC monotherapy was administered to 14 patients; one patient received additionally vitamin A in high dosage and a further patient VP 16 (a podophyllotoxin preparation). The achieved results (a remission rate of 50%) justify the further application of this agent, whereby its relatively limited side effects as well as goood tolerability in elderly patients (over 70 years of age) are emphasized. The inclusion of the preparation in effective combinations is discussed.
本文报道了一项关于细胞抑制剂达卡巴嗪（DTIC）对先前未经治疗、无法手术且经组织学和/或细胞学证实的支气管源性癌疗效的初步研究。共有16例患者，即13例男性和3例女性。14例患者接受了DTIC单一疗法；1例患者额外接受了高剂量维生素A，另1例患者接受了VP 16（一种鬼臼毒素制剂）。所取得的结果（缓解率为50%）证明了该药物可进一步应用，同时强调了其相对有限的副作用以及在老年患者（70岁以上）中的良好耐受性。文中还讨论了将该制剂纳入有效联合治疗方案的问题。
